Table 1. Characteristics of full analysis population.
| EPO (n=89) | Placebo (n=92) | |
|---|---|---|
| Sex | ||
| Male | 47 | 40 |
| Female | 42 | 52 |
| Age (years), median (min–max) | 67 (40–79) | 63.5 (44–79) |
| Weight (kg), median (min–max) | 53.5 (35–102) | 52.8 (37.4–78.1) |
| Tumour | ||
| Small cell lung cancer | 20 (22.5) | 22 (23.9) |
| Non-small cell lung cancer | 40 (44.9) | 38 (41.3) |
| Ovarian cancer | 19 (21.3) | 19 (20.7) |
| Other | 10 (11.2) | 13 (14.1) |
| ECOG performance status | ||
| 0 | 42 (47.2) | 41 (44.6) |
| 1 | 45 (50.6) | 50 (54.3) |
| 2 | 2 (2.2) | 1 (1.1) |
| Haemoglobin (g dl–1), median (min–max) | 9.4 (8.1–11.4) | 9.3 (7.2–11.4) |
| Transferrin saturation (%), median (min–max) | 25.1 (5.4–97.6) | 24.1 (6.4–99.4) |
| Serum endogenous erythropoietin (mIU ml–1), median (min–max) | 43 (7.78–577) | 43.6 (10.5–320) |
Abbreviations: EPO=epoetin-β; ECOG=Eastern Cooperative Oncology Group.